



INFORMATION DISCLOSURE STATEMENT

Applicant : Remacle et al.
App. No : 10/606,162
Filed : June 25, 2003
For : METHOD FOR THE
DETERMINATION OF CELL
ACTIVATION
Examiner : Petersen, Clark D.
Art Unit : 1655

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 4 references to be considered by the Examiner. Also enclosed are 4 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: September 13, 2006

By: _____

Marina L. Gordey
Registration No. 52,950
Agent of Record
Customer No. 20,995
(805) 547-5580

09/18/2006 RMEBRAHT 00000029 10606162

01 FC:1806

180.00 OP

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/606,162
Filing Date	June 25, 2003
First Named Inventor	Jose Remacle
Art Unit	1655
Examiner	Clark D. Petersen
Attorney Docket No.	KLAUS2.002AUS

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	GARBER, M. et al. (2000) "CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 Tat-P-TEFb complex to TAR RNA" <i>Molecular and Cellular Biology</i> 20:6958-6969	
	2	GOLD, M. et al. (1998) "Targeting of CDK8 to a promoter-proximal RNA element demonstrates catalysis-dependent activation of gene expression" <i>Nucleic Acids Research</i> 26:3784-3788	
	3	JAFFER, Z. et al. (2002) "Molecules in focus: p21-activated kinases: three more join the Pak" <i>The International Journal of Biochemistry & Cell Biology</i> 34:713-717.	
	4	SHARMA, P. et al. (1999) "Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation" <i>PNAS USA</i> 96:11156-11160.	

2921480:vr091206

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.